Coherus Oncology, Inc.
CHRSNext catalyst
Casdozokitug
Hepatocellular Carcinoma
Get an email about CHRS's next catalysts
Track Coherus Oncology (CHRS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
CHRS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.22 | FQ end Sep/2026 | Call: tbd
Casdozokitug Phase 2 Est. Readout
Primary completion for Casdozokitug trial (NCT06679985) in Hepatocellular Carcinoma
SourceMarket Overview
Stock performance and key metrics
CHS-0214
Plaque Psoriasis
Etanercept
Rheumatoid Arthritis
CHS-1420
Plaque Psoriasis
Toripalimab-tpzi
Squamous Cell Carcinoma
STC-15 monotherapy
Solid Tumor
Toripalimab
Sinonasal Cancer
Nadunolimab
Metastatic Microsatellite Stable Colorectal Carcinoma
Casdozokitug
Hepatocellular Carcinoma
STC-15 in combination with toripalimab
Solid Tumor
SRF388
Hepatocellular Carcinoma
Toripalimab + Chemotherapy
Head and Neck Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CHS-0214 | Phase 3 | Plaque Psoriasis | - | - |
Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
CHS-1420 | Phase 3 | Plaque Psoriasis | - | - |
Toripalimab-tpzi | Phase 2 | Squamous Cell Carcinoma | - | - |
STC-15 monotherapy | Phase 2 | Solid Tumor | - | - |
Toripalimab | Phase 2 | Sinonasal Cancer | - | - |
Nadunolimab | Phase 2 | Metastatic Microsatellite Stable Colorectal Carcinoma | - | - |
Casdozokitug | Phase 2 | Hepatocellular Carcinoma | - | - |
STC-15 in combination with toripalimab | Phase 2 | Solid Tumor | - | - |
SRF388 | Phase 2 | Hepatocellular Carcinoma | - | - |
Toripalimab + Chemotherapy | Phase 2 | Head and Neck Cancer | - | - |
Hepatocellular Carcinoma
2 drugs in this indication
Plaque Psoriasis
2 drugs in this indication
Rheumatoid Arthritis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Coherus Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in Coherus Oncology, Inc.'s (CHRS) pipeline across Phase 3, Phase 2. Its lead program is CHS-0214 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Coherus Oncology, Inc.'s next FDA catalyst?→
Coherus Oncology, Inc.'s (CHRS) next tracked catalyst is a Phase 2 readout expected September 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CHRS biotech catalysts?→
Add CHRS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Coherus Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.